In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Garnet BioTherapeutics Inc.

Latest From Garnet BioTherapeutics Inc.

SironRX Therapeutics Inc.

SironRX Therapeutics Inc. is betting that a product encoding a protein naturally produced by the body in response to tissue injury, and known to recruit stem cells, can become a drug effective at healing wounds and preventing skin scarring. The start-up got rights to Stromal cell-Derived Factor-1 from Juventas Therapeutics and Cleveland Clinic.

Garnet BioTherapeutics Inc.

Garnet BioTherapeutics has developed a distinct population of "smart" bone-marrow derived cells capable of reducing inflammation and promoting healing. The firm also boasts a proprietary scalable cell expansion technology that can generate billions of patient doses of GBT009 from a single bone marrow donor, the company claims. The company plans to develop therapies to reduce scarring and accelerate healing in post-surgical wound repair and other dermatology applications. It may eventually expand into additional reconstructive and surgical procedures.

Medical Dermatology Gets Under VCs' Skin

In the pharmaceutical industry, dermatology is the new ophthalmology. Like ophtho, dermatology has long been viewed as a pharmaceutical backwater dogged by a diverse set of problems, including a fragmented market, drug delivery challenges, and less than effective therapies. Today's market forces, however, are driving Big Pharma into a more specialized direction, and in the past three years, many - if not all - Big Pharmas have reoriented their pipelines, refocusing on areas of high unmet medical need in the hopes of identifying novel drugs that have a greater chance of passing muster with regulators and succeeding in the marketplace. Freed from the need to pursue blockbuster products, dermatology assets are suddenly more attractive.

Start-Up Previews (05/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Medical Dermatology Gets Under VCs' Skin," features profiles of Garnet Biotherapeutics, Medimetriks and Topica Pharmaceuticals. Plus these Start-Ups Across Health Care: Carolus Therapeutics, Forma Therapeutics, NovaLign Orthopaedics, OmegaGenesis and PercSys.
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Garnet BioTherapeutics Inc.
  • Senior Management
  • Gerri Henwood, CEO
    Sanjay Batra, PhD, SVP, Dev.
  • Contact Info
  • Garnet BioTherapeutics Inc.
    Phone: (610) 240-4150
    1 Great Valley Pkwy
    Ste. 12
    Malvern, PA 19355